Research ArticleExperimental Studies
Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model
RACHEL A. CROSSLEY, ALYSSA MATZ, TERRY DEW, ASHLEY KALINAUSKAS, NICOLE FAUCETTE, BRAD POFF, LAWRENCE K. SILBART and MARK A. SUCKOW
Anticancer Research April 2019, 39 (4) 1699-1703; DOI: https://doi.org/10.21873/anticanres.13275
RACHEL A. CROSSLEY
1Department of Pathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, Storrs, CT, U.S.A.
ALYSSA MATZ
2Department of Molecular and Cell Biology, College of Liberal Arts and Sciences, University of Connecticut, Storrs, CT, U.S.A.
TERRY DEW
3Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A.
ASHLEY KALINAUSKAS
3Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A.
NICOLE FAUCETTE
1Department of Pathobiology and Veterinary Science, College of Agriculture, Health and Natural Resources, University of Connecticut, Storrs, CT, U.S.A.
BRAD POFF
3Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A.
LAWRENCE K. SILBART
2Department of Molecular and Cell Biology, College of Liberal Arts and Sciences, University of Connecticut, Storrs, CT, U.S.A.
MARK A. SUCKOW
3Torigen Pharmaceuticals, Inc., Farmington, CT, U.S.A.
4Department of Biomedical Engineering, University of Kentucky, Lexington, KY, U.S.A.
In this issue
Safety Evaluation of Autologous Tissue Vaccine Cancer Immunotherapy in a Canine Model
RACHEL A. CROSSLEY, ALYSSA MATZ, TERRY DEW, ASHLEY KALINAUSKAS, NICOLE FAUCETTE, BRAD POFF, LAWRENCE K. SILBART, MARK A. SUCKOW
Anticancer Research Apr 2019, 39 (4) 1699-1703; DOI: 10.21873/anticanres.13275
Jump to section
Related Articles
Cited By...
- Autologous Cancer Vaccines: A Precision Immunotherapy Strategy for Veterinary Cancer Patients
- In vitro detection of canine anti-human antibodies following intratumoral injection of the hu14.18-IL2 immunocytokine in spontaneous canine melanoma
- Extracellular matrix scaffold-assisted tumor vaccines induce tumor regression and long-term immune memory
- Use of Conditioned Extracellular Matrix as a Tissue-engineered Tumor Matrisome for Prostate Cancer and Melanoma Immunotherapy







